CN104394883B - 炎性皮肤病症的治疗 - Google Patents

炎性皮肤病症的治疗 Download PDF

Info

Publication number
CN104394883B
CN104394883B CN201380034024.2A CN201380034024A CN104394883B CN 104394883 B CN104394883 B CN 104394883B CN 201380034024 A CN201380034024 A CN 201380034024A CN 104394883 B CN104394883 B CN 104394883B
Authority
CN
China
Prior art keywords
apc
skin
purposes
psoriasis
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380034024.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104394883A (zh
Inventor
克里斯托弗·约翰·杰克逊
薛妹朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZZ Biotech LLC
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902874A external-priority patent/AU2012902874A0/en
Application filed by University of Sydney filed Critical University of Sydney
Publication of CN104394883A publication Critical patent/CN104394883A/zh
Application granted granted Critical
Publication of CN104394883B publication Critical patent/CN104394883B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380034024.2A 2012-07-04 2013-07-04 炎性皮肤病症的治疗 Active CN104394883B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902874 2012-07-04
AU2012902874A AU2012902874A0 (en) 2012-07-04 Treatment of inflammatory skin disorders
PCT/AU2013/000729 WO2014005183A1 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Publications (2)

Publication Number Publication Date
CN104394883A CN104394883A (zh) 2015-03-04
CN104394883B true CN104394883B (zh) 2017-05-31

Family

ID=49881162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380034024.2A Active CN104394883B (zh) 2012-07-04 2013-07-04 炎性皮肤病症的治疗

Country Status (12)

Country Link
US (3) US20150150954A1 (https=)
EP (1) EP2869833B1 (https=)
JP (1) JP6273272B2 (https=)
KR (1) KR102068010B1 (https=)
CN (1) CN104394883B (https=)
AU (1) AU2013286812B2 (https=)
BR (1) BR112015000051A2 (https=)
CA (1) CA2877745C (https=)
ES (1) ES2676422T3 (https=)
IN (1) IN2014DN11181A (https=)
RU (1) RU2662564C2 (https=)
WO (1) WO2014005183A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6273272B2 (ja) * 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
JP2017513944A (ja) * 2014-04-16 2017-06-01 ジージー バイオテック エルエルシー 異常な皮膚瘢痕化の治療
CA2946032C (en) 2014-04-16 2022-06-14 Zz Biotech Llc Use of apc analogue for wound healing
JP2019534266A (ja) 2016-10-14 2019-11-28 江蘇恒瑞医薬股▲ふん▼有限公司 ５員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
US20220079990A1 (en) * 2018-12-26 2022-03-17 Direct Biologics Llc Methods and compositions for treating skin and hair disorders
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
CZ298429B6 (cs) 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
ATE504310T1 (de) 2000-02-04 2011-04-15 Scripps Research Inst Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
AU2001245319A1 (en) * 2000-03-28 2001-10-08 Eli Lilly And Company Methods of treating diseases with activated protein c
WO2002032461A2 (en) 2000-10-18 2002-04-25 Maxygen Aps Protein c or activated protein c-like molecules
JP4351041B2 (ja) * 2001-06-13 2009-10-28 ザ・ユニバーシティ・オブ・シドニー 傷治癒のための処置および組成物
AU2003275948A1 (en) * 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
ATE337003T1 (de) 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7498305B2 (en) 2003-07-08 2009-03-03 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
WO2006072137A1 (en) * 2005-01-07 2006-07-13 Northern Sydney And Central Coast Area Health Service Treatment for autoimmune and inflammatory conditions
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
WO2006136962A2 (en) 2005-06-24 2006-12-28 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
US20100284997A1 (en) 2006-10-31 2010-11-11 Griffin John H Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) * 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
AU2010231514A1 (en) * 2009-04-01 2011-11-03 Rappaport Family Institute For Research In The Medical Sciences A method of regulating proliferation and differentiation of keratinocytes
JP6273272B2 (ja) * 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
CA2946032C (en) * 2014-04-16 2022-06-14 Zz Biotech Llc Use of apc analogue for wound healing
JP2017513944A (ja) * 2014-04-16 2017-06-01 ジージー バイオテック エルエルシー 異常な皮膚瘢痕化の治療
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法

Also Published As

Publication number Publication date
AU2013286812B2 (en) 2017-04-20
EP2869833B1 (en) 2018-04-04
WO2014005183A1 (en) 2014-01-09
US11617785B2 (en) 2023-04-04
JP6273272B2 (ja) 2018-01-31
CN104394883A (zh) 2015-03-04
JP2015521632A (ja) 2015-07-30
KR102068010B1 (ko) 2020-01-20
IN2014DN11181A (https=) 2015-10-02
CA2877745A1 (en) 2014-01-09
BR112015000051A2 (pt) 2017-06-27
KR20150036351A (ko) 2015-04-07
ES2676422T3 (es) 2018-07-19
RU2662564C2 (ru) 2018-07-26
AU2013286812A1 (en) 2015-01-22
US20200276281A1 (en) 2020-09-03
US20150150954A1 (en) 2015-06-04
US20170080062A1 (en) 2017-03-23
EP2869833A1 (en) 2015-05-13
EP2869833A4 (en) 2015-11-18
HK1204573A1 (en) 2015-11-27
CA2877745C (en) 2021-11-30
RU2015103510A (ru) 2016-08-27

Similar Documents

Publication Publication Date Title
CN104394883B (zh) 炎性皮肤病症的治疗
Shimizu et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung
CN1961958B (zh) 改善伤口愈合的方法
Oyamada et al. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion
EP2498806B1 (en) Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
JP2009510091A (ja) 羊膜調製物及び精製組成物及びその使用方法
EP3624832B1 (en) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
JP6846063B2 (ja) 異常な皮膚瘢痕化の治療
KR20110131187A (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
US20190328770A1 (en) Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
WO2022002160A1 (zh) Pcsk9抑制剂在制备治疗多种疾病产品中的应用
AU2001261378A1 (en) Method and composition for the treatment of angiogenesis
EP1280546A1 (en) Method and composition for the treatment of angiogenesis
HK1204573B (en) Treatment of inflammatory skin disorders
CN114432447A (zh) Pcsk9抑制剂在制备治疗肺纤维化药物中的应用
Cole Dermatologic Therapies
Khachemoune et al. Psoriasis: disease management with a brief review of new biologics
Bubna et al. Brodalumab: Looking beyond psoriasis
Bubna IL-17 Antagonists
WO2012025746A1 (en) Medical use of heparin-binding egf-like growth factor (hb-egf)
HK1235306B (zh) 治疗异常皮肤瘢痕形成
Alexander Retinoid and Pentoxifylline-Induced Modulation of Human Melanoma Cell Metastasis
Fukaura et al. BioDrugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204573

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180126

Address after: American Texas

Patentee after: ZZ Biotechnology Co., Ltd.

Address before: New South Wales Australia

Patentee before: Univ. of Sydney

TR01 Transfer of patent right
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1204573

Country of ref document: HK